Ciplukan

Small molecule

UUniversitas Padjadjaran

Ciplukan is one of 39 small molecule programs targeting Psoriasis Vulgaris. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriasis VulgarisActive, not recruiting

Psoriasis VulgarisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

107 competitors in Psoriasis Vulgaris

#DrugCompanyPhaseTrials

Omvoh

Cimzia

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Sorilux

LEO Pharma

Phase 3

2 6

Orencia

Bristol-Myers Squibb

Phase 2

3 7

Zinbryta

Roche

Phase 2

2 8

Trexall

Alnylam Pharmaceuticals

Phase 2

1 9

Asmanex

LEO 43204

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis Vulgaris1 trial

The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions

Enrolling by invitation·UUniversitas Padjadjaran·Phase 1/2·NCT06887322·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ciplukan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciplukan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciplukan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitas Padjadjaran company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversitas Padjadjaran

Ciplukan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis Vulgaris1 trial

References

Drug Info

Quick Facts

Related News